Gilead Submits NDA For Ambrisentan For PAH
This article was originally published in The Pink Sheet Daily
Executive Summary
Company has requested a priority review, but anticipates receiving a standard 10-month review, pushing the user fee date to Oct. 18.
You may also be interested in...
FDA To Review Gilead’s Ambrisentan And Encysive’s Thelin Back-To-Back
The agency granted Gilead’s pulmonary hypertension candidate a priority review, setting a June 18 user fee date that falls days after the review timeline for Thelin.
FDA To Review Gilead’s Ambrisentan And Encysive’s Thelin Back-To-Back
The agency granted Gilead’s pulmonary hypertension candidate a priority review, setting a June 18 user fee date that falls days after the review timeline for Thelin.
Gilead Ramps Up For Ambrisentan; Calls For 75 To 100 Sales Reps
Company plans to go toe-to-toe with PAH competitors, CEO tells JP Morgan Healthcare Conference.